The Fraud Section of the U.S. Department of Justice (“DOJ”) Criminal Division (the “Fraud Section”) recently published an Evaluation of Corporate Compliance Programs (the “Evalu...
On January 17, 2017, the Department of Justice (“DOJ”) announced that British multinational manufacturer Rolls-Royce plc (“Rolls-Royce” or the “Company”) had entered into a De...
On January 13, 2017, the Supreme Court granted certiorari in Kokesh v. SEC to resolve a circuit split on the issue of whether the five-year statute of limitations in 28 U.S.C. § 2462—w...
The Tenth and D.C. Circuit Courts of Appeal have come to opposite conclusions in response to constitutional challenges to the Securities Exchange Commission’s (the “SEC’s”) appoin...
On January 4, the U.S. Federal District Court for the Northern District of California issued a decision in a case brought by shareholders against Volkswagen arising out of the well-public...
In late December 2016, Teva Pharmaceutical Industries Ltd. (“Teva”), the world’s largest generic pharmaceutical manufacturer, entered into a deferred prosecution agreement (“DPA?...
On Wednesday, December 21, 2016, Brazilian construction conglomerate Odebrecht S.A. and its affiliate Braskem S.A. pled guilty in the United States District Court for the Eastern District...
The SEC issued two orders concerning violations of Exchange Act Rule 21F-17 this week. On December 19, the Commission issued an order concerning NeuStar Inc., a technology company based ...
To be guilty of insider trading, a tipper of inside information must receive a “personal benefit” in exchange for his tips. On December 6, 2016, the Supreme Court unanimously held in ...
Life sciences companies are frequent targets of securities litigation. Often, when a company discloses bad news about a developing device or drug, the company’s stock price drops and pl...
